^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ixempra (ixabepilone) (Microtubule inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Invasive Breast Cancer: HER-2 negative...Other Recommended Regimens…Ixabepilone…
Source:
Title:
Ixabepilone + Carboplatin Metastatic Breast Cancer
Excerpt:
...Has measurable metastatic and or locally unresectable breast cancer with documented HER2 negative (-) disease 2....
Trial ID:
Source:
Title:
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Excerpt:
...6 HER2-negative status....
Trial ID:
More C2 evidence
Source:
Title:
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Excerpt:
...- Node-positive patients: triple-negative* tumor (HER2 negative, estrogen-receptor [ER] negative, and progesterone receptor [PR] negative) OR double-negative (HER2 negative, PR negative, and ER+)...
Trial ID:
Source:
Title:
Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Prediction (DRP) after failure of an anthracycline and a taxane
Excerpt:
...Patients with hormone receptor positive and HER2 negative or triple negative primary tumor.5. ...
Trial ID:
Source:
Title:
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
Excerpt:
...- Patients with histologic confirmation of invasive HER2/neu-negative breast cancer (immunohistochemistry [IHC] 0-1+ or fluorescence in situ hybridization [FISH]-negative) that have received complete anthracycline and taxane neoadjuvant systemic therapy and that at the time of surgery are expected to have significant residual disease....
Trial ID:
Source:
Title:
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Excerpt:
...The tumor must have been determined to be HER2-negative as follows:...
Trial ID:
Source:
Title:
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
Excerpt:
...HER2-negative tumor status....
Trial ID:
Source:
Title:
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Excerpt:
...HER2 negative tumors....
Trial ID:
Source:
Title:
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
Excerpt:
...- Female subjects with triple negative (ER, PR, and HER2 negative) locally advanced non-resectable and/or metastatic breast cancer...
Trial ID:
Source:
Title:
Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)
Excerpt:
...- Diagnosis of HER-2 negative (HER-2 ...
Trial ID:
